Core Viewpoint - BioMérieux completed the acquisition of Accellix in January 2026, enhancing its pharmaceutical quality control business and supporting advancements in cell and gene therapy, ultimately improving patient treatment outcomes [1][2]. Group 1: Acquisition Details - The acquisition of Accellix, which specializes in rapid automated flow cytometry solutions for quality control in cell and gene therapy, was valued at approximately 289 million RMB [5]. - This strategic move positions BioMérieux to address the critical need for efficient quality control in the rapidly growing and demanding cell and gene therapy market [5]. Group 2: Industry Context - Cell and gene therapies are considered "living" drugs with short production windows and precious samples, necessitating high-speed, reliable, and repeatable quality control [4]. - Traditional large flow cytometers are inadequate for real-time, on-site testing in production environments, highlighting the importance of Accellix's platform in transforming quality control into an efficient industrial process [5]. Group 3: Strategic Acquisitions - BioMérieux has undertaken a series of strategic acquisitions to consolidate its technological leadership and expand into new markets, including: - The acquisition of BioFire Diagnostics in 2013 for approximately 486 million USD, gaining access to the FilmArray molecular diagnostic system [6]. - The acquisition of Specific Diagnostics in 2022 to enhance rapid antibiotic susceptibility testing capabilities [7]. - The acquisition of Day Zero Diagnostics in 2025 to tackle challenges in diagnosing complex and unknown pathogen infections [7].